New hope for Tough-to-Treat blood cancer: advanced drug trial seeks to outperform current options
NCT ID NCT07377578
Summary
This study is testing whether a new drug called rocbrutinib works better than currently approved drugs for people with mantle cell lymphoma that has come back or stopped responding to prior treatment. About 394 participants will be randomly assigned to receive either rocbrutinib or one of the standard BTK inhibitor drugs chosen by their doctor. The main goal is to see which treatment keeps the cancer from getting worse for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITINGNanning, Guangxi, 530021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.